ArticleScientific reports2025
Development of a high-throughput MassARRAY-based single assay for the characterization of Streptococcus suis species and serotypes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Public Awareness and Molecular Characterization ofVeterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Streptococcus suis is a significant porcine pathogen and zoonotic agent responsible for infectious diseases in humans worldwide. It is classified into 29 serotypes, each with varying geographical prevalence and pathogenicity. Hence, serotyping of S. suis is crucial for active surveillance, outbreak monitoring, and infection control. This study developed a novel MassARRAY-based single assay to simultaneously identify S. suis species and differentiate all 29 serotypes. The assay targeted glutamate dehydrogenase (gdh) and recombination/repair protein (recN) for species identification, and capsular polysaccharide (cps) genes for serotyping. Based on single nucleotide polymorphisms (SNPs) at position 483 of cpsK gene, the assay accurately distinguished between two pairs of serotypes: ½ and 2, as well as 1 and 14. The assay, validated with genomic DNA from 105 whole-genome sequencing (WGS)-confirmed isolates, demonstrated 100% specificity and sensitivity for both species identification and serotyping. In the evaluation with 143 field isolates, the results demonstrated perfect agreement between the MassARRAY-based assay and WGS for species identification, with 100% sensitivity and specificity, and for serotyping, with 99.15% sensitivity and 100% specificity (κ-value = 0.98). The agreement between WGS-based serotyping and multiplex PCR serotyping was substantial (κ = 0.65). Moreover, the results showed that the limit of detection for both species and serotypes ranged from 1 to 10 pg of gDNA per reaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.